Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin

Transplantation Proceedings

Volumn 44, Issue 7, 2012, Pages 1926-1927

  Caroti, L ^a   Zanazzi, M ^a   Paudice, N ^a   Tsalouchos, A ^a   Carta, P ^a   Larti, A ^a   Pimpinelli, N ^a   Moscarelli, L ^a   Salvadori, M ^a   Bertoni, E ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; CANCER RECURRENCE; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SURGICAL PATIENT;

CALCINEURIN; CARCINOMA, SQUAMOUS CELL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY TRANSPLANTATION; SIROLIMUS; SKIN NEOPLASMS;

EID: 84866324006     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.06.035     Document Type: Conference Paper

References (3)

1. G.E. Koehl, H.J. Schlitt, E.K. Geissler Rapamycin and tumor growth: mechanism behind its anticancer activity Transplant Rev 19 2005 20
2. E. Gonzalez, A. Andres, N. Polanco Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation Transplant Proc 41 2009 2332
3. R.P. Carrol, D.S. Segundo, K. Hollowood Immune phenotype predicts risk for posttransplantation squamous cell carcinoma J Am Soc Nephrol 21 2010 713